OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001621227

Adaptimmune Therapeutics PLC (ADAPY)

Adaptimmune Therapeutics PLC (CIK 0001621227, ticker ADAPY) reported revenue of $178.03 million ($178,032,000) for FY2024 (2024-01-01 to 2024-12-31) and net income of -$70.81 million (-$70,814,000) for FY2024 (2024-01-01 to 2024-12-31), as filed in its 10-K filed 2025-03-24 (accession 0001558370-25-003544).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001621227
TickersADAPY (OTC)
EINnot in EDGAR (or not a valid EIN)
SIC industry code2836 Biological Products, (No Diagnostic Substances)
State or country of incorporationX0
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_2gzxest2mpdz23gf088zb0z2r6
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$178,032,000FY20242024-01-01 to 2024-12-3110-K2025-03-240001558370-25-003544RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$70,814,000FY20242024-01-01 to 2024-12-3110-K2025-03-240001558370-25-003544NetIncomeLoss
Total assets$245,963,000FY2024as of 2024-12-3110-K2025-03-240001558370-25-003544Assets
Total liabilities$234,114,000FY2024as of 2024-12-3110-K2025-03-240001558370-25-003544Liabilities
Stockholders' equity$11,849,000FY2024as of 2024-12-3110-K2025-03-240001558370-25-003544StockholdersEquity
Operating cash flow-$73,206,000FY20242024-01-01 to 2024-12-3110-K2025-03-240001558370-25-003544NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.05 per shareFY20242024-01-01 to 2024-12-3110-K2025-03-240001558370-25-003544EarningsPerShareDiluted
Shares outstanding1,543,391,646 sharesFY2024as of 2025-03-2110-K2025-03-240001558370-25-003544EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2015-2024, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20242024-01-01 to 2024-12-31$178,032,00010-K2025-03-240001558370-25-003544
RevenueFY20232023-01-01 to 2023-12-31$60,281,00010-K2025-03-240001558370-25-003544
RevenueFY20222022-01-01 to 2022-12-31$27,148,00010-K2025-03-240001558370-25-003544
RevenueFY20212021-01-01 to 2021-12-31$6,149,00010-K2024-03-060001558370-24-002537
RevenueFY20202020-01-01 to 2020-12-31$3,958,00010-K2023-03-060001558370-23-002907
RevenueFY20192019-01-01 to 2019-12-31$1,122,00010-K2022-03-140001558370-22-003489
RevenueFY20182018-01-01 to 2018-12-31$59,505,00010-K2021-02-250001558370-21-001827
RevenueFY20172017-01-01 to 2017-12-31$37,833,00010-K2019-02-270001558370-19-001209
RevenueFY20162016-01-01 to 2016-12-31$14,198,00010-K2019-02-270001558370-19-001209
Net incomeFY20242024-01-01 to 2024-12-31-$70,814,00010-K2025-03-240001558370-25-003544
Net incomeFY20232023-01-01 to 2023-12-31-$113,871,00010-K2025-03-240001558370-25-003544
Net incomeFY20222022-01-01 to 2022-12-31-$165,456,00010-K2025-03-240001558370-25-003544
Net incomeFY20212021-01-01 to 2021-12-31-$158,090,00010-K2024-03-060001558370-24-002537
Net incomeFY20202020-01-01 to 2020-12-31-$130,092,00010-K2023-03-060001558370-23-002907
Net incomeFY20192019-01-01 to 2019-12-31-$137,165,00010-K2022-03-140001558370-22-003489
Net incomeFY20182018-01-01 to 2018-12-31-$95,514,00010-K2021-02-250001558370-21-001827
Net incomeFY20172017-01-01 to 2017-12-31-$70,138,00010-K2019-02-270001558370-19-001209
Net incomeFY20162016-01-01 to 2016-12-31-$71,579,00010-K2019-02-270001558370-19-001209

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2025-08-132025-06-300001558370-25-011307adap-20250630x10q.htm
10-Q2025-05-132025-03-310001558370-25-007571adap-20250331x10q.htm
10-K2025-03-242024-12-310001558370-25-003544adap-20241231x10k.htm
10-Q2024-11-132024-09-300001558370-24-015532adap-20240930x10q.htm
10-Q2024-08-122024-06-300001558370-24-011798adap-20240630x10q.htm
10-Q2024-05-152024-03-310001558370-24-008287adap-20240331x10q.htm
10-K2024-03-062023-12-310001558370-24-002537adap-20231231x10k.htm
10-Q2023-11-082023-09-300001558370-23-018265adap-20230930x10q.htm
10-Q2023-08-092023-06-300001558370-23-014250adap-20230630x10q.htm
10-Q2023-05-122023-03-310001558370-23-009595adap-20230331x10q.htm
10-K2023-03-062022-12-310001558370-23-002907adap-20221231x10k.htm
10-Q2022-11-082022-09-300001558370-22-016869adap-20220930x10q.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001621227published by the sourcedata.sec.gov/submissions/CIK0001621227.json2026-10-21

Former names

NameFromTo
Adaptimmune Ltd2014-10-022015-03-17

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001621227.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001621227.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001621227" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001621227/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001621227/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1621227"}

On SEC EDGAR

About this data